Abingworth LLP
- SEC CIK
- 0001397144
- Latest filing
- Feb 10, 2023
Holdings in Q3 2022
Holdings as of Sep 30, 2022, filed Nov 10, 2022. Long positions only; changes compare share counts with Q2 2022.
- Positions
- 19
- −2 vs. Q2 2022
- Portfolio value
- $292.5M
- −$19.9M (−6.4%) vs. Q2 2022
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| PCVXVaxcyte, Inc. | COM | 4,168,718 | $100.0M | 34.2% | 00.0% | Unchanged | History |
| VERAVera Therapeutics, Inc. | CL A | 2,960,231 | $63.1M | 21.6% | 00.0% | Unchanged | History |
| HLVXHilleVax, Inc. | COM | 1,838,486 | $31.4M | 10.7% | 00.0% | Unchanged | History |
| ACETAdicet Bio, Inc. | COM | 2,115,385 | $30.0M | 10.3% | 00.0% | Unchanged | History |
| VRNAVerona Pharma plc | SPONSORED ADS | 2,457,500 | $25.1M | 8.6% | 00.0% | Unchanged | History |
| PHATPhathom Pharmaceuticals, Inc. | COM | 1,435,106 | $15.9M | 5.4% | 00.0% | Unchanged | History |
| OKUROnKure Therapeutics, Inc. | COM | 2,073,957 | $6.95M | 2.4% | 00.0% | Unchanged | History |
| JSPRJasper Therapeutics, Inc. | COM | 5,628,558 | $4.44M | 1.5% | 00.0% | Unchanged | History |
| NCNANuCana plc | SPONSORED ADR | 3,333,333 | $3.40M | 1.2% | 00.0% | Unchanged | History |
| EFTReFFECTOR Therapeutics, Inc. | COM | 4,822,114 | $2.73M | 0.9% | 00.0% | Unchanged | History |
| PRTKParatek Pharmaceuticals, Inc. | COM | 1,041,131 | $2.68M | 0.9% | 00.0% | Unchanged | History |
| SPRBSpruce Biosciences, Inc. | COM | 1,792,518 | $2.47M | 0.8% | +1,792,518 | New | History |
| SLNOSoleno Therapeutics Inc | COM | 1,201,506 | $2.01M | 0.7% | 00.0% | UnchangedConverted for a 1-for-15 split | History |
| SIENProject Sage Oldco, Inc. | COM | 1,673,589 | $1.07M | 0.4% | 00.0% | Unchanged | History |
| CBAYCymaBay Therapeutics, Inc. | COM | 131,036 | $457.0K | 0.2% | 00.0% | Unchanged | History |
| XCURExicure, Inc. | COM NEW | 281,636 | $439.0K | 0.2% | +281,636 | New | History |
| MTEMMolecular Templates, Inc. | COM | 200,000 | $150.0K | 0.1% | 00.0% | Unchanged | History |
| SYRESpyre Therapeutics, Inc. | COM | 240,500 | $127.0K | <0.1% | 00.0% | Unchanged | History |
| OBSVObsEva SA | COM | 87,999 | $13.0K | <0.1% | 00.0% | Unchanged | History |
Sold out since Q2 2022 (4)
Positions held at the end of Q2 2022 that are gone from this filing.
| Security | Class | Shares in Q2 2022 | Value in Q2 2022 | % of portfolio in Q2 2022 | History |
|---|---|---|---|---|---|
| SRRASierra Oncology, Inc. | COM | 1,314,127 | $72.3M | 23.1% | History |
| Spruce BioE5209E109 | Common | 1,792,518 | $3.10M | 1.0% | – |
| XCURExicure, Inc. | COM | 281,636 | $594.0K | 0.2% | History |
| OCGNOcugen, Inc. | Common | 7,111 | $16.0K | <0.1% | History |